Skip to main content
SPT logo

SPT — Investor Relations & Filings

Ticker · 1789 ISIN · TW0001789006 TW Manufacturing
Open in API
Filings indexed 2,236 across all filing types
Latest filing 2026-05-27 Regulatory Filings
Country TW Taiwan
Listing TW 1789

About SPT

https://www.scinopharm.com/tw

ScinoPharm Taiwan, Ltd. is a global provider of high-quality Active Pharmaceutical Ingredients (APIs) and comprehensive Contract Development and Manufacturing Organization (CDMO) services. The company specializes in process research, development, and cGMP production, maintaining a leadership position in oncology APIs. Its portfolio covers therapeutic areas including cancer, hematology, metabolic disorders, and central nervous system diseases. ScinoPharm offers one-stop solutions encompassing peptide synthesis, API process development, and the manufacturing of sterile injectables and complex generics. The company is distinguished by its expertise in high-barrier pharmaceutical technologies and adherence to stringent international regulatory standards, such as the U.S. FDA. Serving both generic and innovative drug sectors, it leverages advanced R&D and integrated manufacturing to support global healthcare markets.

Recent filings

Filing Released Lang Actions
公司基本資料
Regulatory Filings Classification · 90% confidence The document is a standardized corporate profile disclosure from Taiwan’s "公開資訊觀測站", listing company name, stock code, business scope, auditor, share capital, listing dates, contact details, and governance URLs. It does not contain actual financial statements, earnings discussion, or management analysis, nor is it announcing a specific report. It is a general regulatory information filing and thus falls into the Regulatory Filings (RNS) category.
2026-05-27 Chinese
115年年報及股東會資料 — 2026_1789_20260527F14.pdf
Governance Information Classification · 90% confidence The document is a detailed internal policy setting out procedures, approval thresholds, definitions, and governance controls for the company’s acquisition or disposal of assets. It is not an earnings release, financial report, or announcement of a report, but rather a governance manual. It fits the definition of Governance Information (CGR) as it details company internal rules and governance practices.
2026-05-27 Chinese
115年年報及股東會資料 — 2026_1789_20260527FE2.pdf
AGM Information Classification · 92% confidence The document is titled "Handbook for 2026 Annual General Shareholders’ Meeting" and consists of the AGM agenda, proposals (business report, audit committee review, financial statements, remuneration, amendments to articles, etc.), and appendices of reports to be tabled at the Annual General Meeting. It is not the full annual report itself but meeting materials presented at the AGM. Therefore, it classifies as AGM Information.
2026-05-27 English
115年年報及股東會資料 — 2026_1789_20260527FE1.pdf
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a formal notice of the upcoming 2026 Annual General Shareholders’ Meeting, detailing the meeting date, agenda items (reports, ratifications, discussions), dividend proposal, share registration closure, and proxy voting procedures. It is sent to shareholders to inform and solicit votes. This aligns with the definition of Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders requesting votes for a meeting.
2026-05-27 English
115年年報及股東會資料 — 2026_1789_20260527F02.pdf
AGM Information Classification · 95% confidence The document is the “民國115年股東常會議事手冊” (Annual Shareholders’ Meeting Agenda Manual) for ScinoPharm Taiwan, Ltd., containing the AGM agenda, proposals (reports, approvals, discussions), and attachments (annual business report, audit committee report, audited financial statements, earnings distribution table, charter amendments, governance procedures, etc.). It is meeting materials provided to shareholders rather than the full Annual Report itself or a simple announcement. Therefore it falls under AGM Information (AGM-R).
2026-05-27 Chinese
115年第1季財務報告書 — 202601_1789_AI1.pdf
Interim / Quarterly Report Classification · 93% confidence The document is titled “合併財務報告暨會計師核閱報告 民國115年及114年第一季” and contains full consolidated interim financial statements (balance sheet, income statement, cash flows, equity changes, notes) for Q1 (a period shorter than a fiscal year) along with an auditor’s review report. This is not just a notice or summary, but the complete interim financial report prepared under IFRS 34 “Interim Financial Reporting.” Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-14 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.